0001752724-21-269098.txt : 20211214
0001752724-21-269098.hdr.sgml : 20211214
20211214121643
ACCESSION NUMBER: 0001752724-21-269098
CONFORMED SUBMISSION TYPE: N-CEN
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20210930
FILED AS OF DATE: 20211214
DATE AS OF CHANGE: 20211214
EFFECTIVENESS DATE: 20211214
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: VANGUARD QUANTITATIVE FUNDS
CENTRAL INDEX KEY: 0000799127
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: N-CEN
SEC ACT: 1940 Act
SEC FILE NUMBER: 811-04526
FILM NUMBER: 211490201
BUSINESS ADDRESS:
STREET 1: 100 VANGUARD BLVD
STREET 2: P O BOX 2600
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 6106691000
MAIL ADDRESS:
STREET 1: 100 VANGUARD BLVD
STREET 2: PO BOX 2600
CITY: VALLEY FORGE
STATE: PA
ZIP: 19482
FORMER COMPANY:
FORMER CONFORMED NAME: VANGUARD QUANTITATIVE FUNDS /
DATE OF NAME CHANGE: 20010503
0000799127
S000002913
Vanguard Growth and Income Fund
C000007979
Investor Shares
VQNPX
C000007980
Admiral Shares
VGIAX
N-CEN
1
primary_doc.xml
X0404
N-CEN
LIVE
0000799127
XXXXXXXX
811-04526
true
false
false
N-1A
true
VANGUARD QUANTITATIVE FUNDS
811-04526
0000799127
5493007AJT3TIGZKYP66
100 VANGUARD BOULEVARD
MALVERN
19355
US-PA
US
6106691000
State Street Bank and Trust
One Lincoln Street
Boston
20111
617-662-3839
The accounts, books, and other documents required to be maintained by Registrant pursuant to section 31(a) of the Investment Company Act of 1940 and the Rules thereunder.
N
N
N-1A
1
Y
Andre F. Perold
N/A
N
Mortimer J. Buckley
002167630
Y
David Thomas
N/A
N
Mark Loughridge
N/A
N
Emerson U. Fullwood
N/A
N
Sarah Bloom Raskin
N/A
N
Peter F. Volanakis
N/A
N
Scott C. Malpass
N/A
N
F. Joseph Loughrey
N/A
N
Amy Gutmann
N/A
N
Deanna Mulligan
N/A
N
John E. Schadl
006931790
100 Vanguard Boulevard
Malvern
19355
XXXXXX
N
N
N
N
N
N
VANGUARD MARKETING CORP.
8-21570
000007452
N/A
Y
N
PRICEWATERHOUSECOOPERS LLP
000000238
5493002GVO7EO8RNNS37
N
N
N
N
N
N
N
VANGUARD GROWTH AND INCOME FUND
S000002913
BZQEUHY2KE1ZMR7IWO60
N
2
0
0
N/A
N
N
Y
N
N
The Vanguard Group, Inc.
5493002789CX3L0CJP65
Y
N
Cash collateral reinvestment fee
Administrative fee
6580985.88999999
246017.86000000
Rule 32a-4 (17 CFR 270.32a-4)
Rule 17a-7 (17 CFR 270.17a-7)
N
N
N
N
Los Angeles Capital Management and Equity Research, Inc.
801-60934
000119033
549300DZCL1LRBNVU327
N
The Vanguard Group, Inc.
801-11953
000105958
5493002789CX3L0CJP65
N
D. E. Shaw Investment Management, LLC
801-64222
000135284
549300ZUDX4FNDGUSO63
N
The Vanguard Group, Inc.
084-00772
5493002789CX3L0CJP65
Y
N
N
Refinitiv US LLC
20-4530702
TIN
N
Markit North America INC
13-4153988
TIN
N
ICE Data Pricing and Refernce Data LLC
13-36687789
TIN
N
Markit Group Limited
549300HLPTRASHS0E726
GB
N
Bloomberg Finance LP
5493001KJTIIGC8Y1R12
N
ITG Analytics Inc
41-2190282
TIN
N
JPMorgan Chase Bank
7H6GLXDRUGQFU57RNE97
N
N
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
N
Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1))
N
The Vanguard Group, Inc.
5493002789CX3L0CJP65
Y
N
N
State Street Bank and Trust Company
571474TGEMMWANRLN572
N
Y
THE VANGUARD GROUP, INC.
5493002789CX3L0CJP65
Y
N
Y
Instinet, LLC
008-23669
000007897
549300MGMN3RKMU8FT57
42196.87999999
BofA Securities, Inc.
008-69787
000283942
549300HN4UKV1E2R3U73
36187.33999999
Sanford C. Bernstein & Co., LLC
008-52942
000104474
549300I7JYZHT7D5CO04
40680.72000000
Goldman Sachs & Co. LLC
008-00129
000000361
FOR8UP27PHTHYVLBNG30
103151.26999999
UBS Securities LLC
008-22651
000007654
T6FIZBDPKLYJKFCRVK44
57570.00000000
Jefferies LLC
008-15074
000002347
58PU97L1C0WSRCWADL48
202570.39000000
Barclays Capital Inc.
008-41342
000019714
AC28XWWI3WIBK2824319
39520.74999999
Morgan Stanley & Co. LLC
008-15869
000008209
9R7GPTSO7KV3UQJZQ078
146955.17999999
J.P. Morgan Securities LLC
008-35008
000000079
ZBUT11V806EZRVTWT807
56256.93000000
Credit Suisse Securities (USA) LLC
008-00422
000000816
1V8Y6QCX6YMJ2OELII46
91509.57999999
872139.24999993
Vanguard Market Liquidity Fund
N/A
N/A
1I6HV0TLSTR3A4XQ6L78
5530568849.00000000
Vanguard U.S. Growth Fund
N/A
N/A
4IESARCYK2P68FL7C831
9473697.09999999
BofA Securities, Inc.
008-69787
000283942
549300HN4UKV1E2R3U73
80502976.09000000
Morgan Stanley & Co. LLC
008-15869
000008209
9R7GPTSO7KV3UQJZQ078
1121427814.80999990
J.P. Morgan Securities LLC
008-35008
000000079
ZBUT11V806EZRVTWT807
915408.78000000
Deutsche Bank Securities Inc.
008-17822
000002525
9J6MBOOO7BECTDTUZW19
899783.44000000
6743788529.21999989
Y
12720836000.37583400
Committed
4300000000.00000000
N
N
N
N
true
INTERNAL CONTROL RPT
2
quantitativefunds11.19.txt
Report of Independent Registered Public Accounting Firm
To the Board of Fundees of Vanguard Quantitative Funds and
Shareholders of Vanguard Growth and Income Fund
In planning and performing our audit of the financial statements of
Vanguard Growth and Income Fund (constituting Vanguard Quantitative
Funds, referred to hereafter as the "Fund") as of and for the year ended
September 30, 2021, in accordance with the standards of the Public
Company Accounting Oversight Board (United States) ("PCAOB"), we
considered the Fund's internal control over financial reporting, including
controls over safeguarding securities, as a basis for designing our
auditing procedures for the purpose of expressing our opinion on the
financial statements and to comply with the requirements of Form N-
CEN, but not for the purpose of expressing an opinion on the
effectiveness of the Fund's internal control over financial reporting.
Accordingly, we do not express an opinion on the effectiveness of the
Fund's internal control over financial reporting.
The management of the Fund is responsible for establishing and
maintaining effective internal control over financial reporting. In fulfilling
this responsibility, estimates and judgments by management are
required to assess the expected benefits and related costs of controls. A
company's internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles.
A company's internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance of records
that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the assets of the company; (2) provide reasonable
assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of
management and directors of the company; and (3) provide reasonable
assurance regarding prevention or timely detection of unauthorized
acquisition, use or disposition of a company's assets that could have a
material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk
that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may
deteriorate.
A deficiency in internal control over financial reporting exists when the
design or operation of a control does not allow management or
employees, in the normal course of performing their assigned functions,
to prevent or detect misstatements on a timely basis. A material
weakness is a deficiency, or a combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable possibility
that a material misstatement of the company's annual or interim financial
statements will not be prevented or detected on a timely basis.
Our consideration of the Fund's internal control over financial reporting
was for the limited purpose described in the first paragraph and would
not necessarily disclose all deficiencies in internal control over financial
reporting that might be material weaknesses under standards
established by the PCAOB. However, we noted no deficiencies in the
Fund's internal control over financial reporting and its operation,
including controls over safeguarding securities, that we consider to be a
material weakness as defined above as of September 30, 2021.
This report is intended solely for the information and use of the Board of
Trustees of Vanguard Quantitative Funds and the Securities and
Exchange Commission and is not intended to be and should not be used
by anyone other than these specified parties.
/s/PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
November 19, 2021